ImageneBio

Update in progress

IMA (NasdaqCM)

ImageneBio, Inc. is a clinical-stage biopharmaceutical company focused on therapies for immunological, autoimmune, and inflammatory diseases. Its lead candidate, IMG-007, is a non-depleting anti-OX40 monoclonal antibody that binds the OX40 receptor on activated T cells to prevent interaction with its ligand. IMG-007 is in Phase 1b/2a trials. The firm was formerly Ikena Oncology, renamed in July 2025, and is headquartered in San Diego, California.